Astragaloside IV (ASV), which has several pharmacological abilities, shows potential therapeutic effects on certain cancers by regulating the expression of long noncoding RNA (lncRNA). However, the anticancer role that ASV plays by regulating lncRNAs in breast cancer remains unknown. In this study, we first demonstrated that the lncRNA of TRHDE antisense RNA 1 (TRHDE-AS1) was downregulated in breast cancer tissues and cells. Low TRHDE-AS1 expression is associated with poor outcomes in patients with breast cancer and potentially contributes to the aggressive tumor biology of breast cancer. Furthermore, ASV significantly increased TRHDE-AS1 expression in a dose- and time-dependent manner in breast cancer cells. By upregulating TRHDE-AS1, ASV repressed breast cancer cell growth and metastasis both in vitro and in vivo. Taken together, our data indicated that TRHDE-AS1 participates in the anticancer role of ASV in breast cancer, which provides evidence for the application of ASV for breast cancer therapy.

具有多种药理作用的黄芪甲苷IV（ASV）通过调节长非编码RNA（lncRNA）的表达，对某些癌症具有潜在的治疗作用。但是，ASV通过调节lncRNA在乳腺癌中发挥的抗癌作用仍然未知。在这项研究中，我们首先证明了TRHDE反义RNA 1（TRHDE-AS1）的lncRNA在乳腺癌组织和细胞中被下调。TRHDE-AS1低表达与乳腺癌患者的不良预后相关，并可能促进乳腺癌的侵袭性肿瘤生物学。此外，ASV以剂量和时间依赖性方式显着增加乳腺癌细胞中TRHDE-AS1的表达。通过上调TRHDE-AS1，ASV可以在体内外抑制乳腺癌细胞的生长和转移。在一起